TheEdgeResearch
Home / Stocks / TDAC

Translational Development Acquisition Corp. (TDAC)

NASDAQ Financial Services Shell Companies
$10.87 ▲ +0.09%
Market Cap
$267.7M
Sector
Financial Services
Industry
Shell Companies
Beta
0.01
52-Wk Range
10.34-10.95
CEO
Michael Hoffman
Country
US
Currency
USD

Translational Development Acquisition Corp. operates in the Shell Companies industry of the Financial Services sector, headquartered in New York City, NY, US. The stock last traded at $10.87, up 0.09% on the session, giving a market capitalisation of $267.7M. On trailing twelve-month figures it carries a trailing P/E of 42.20, a net margin of 0.0%. Its beta of 0.01 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
42.20
Price / Sales
0.00
Price / Book
1.22
EV / EBITDA
-203.87
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.01
Current ratio
0.06
Dividend yield
0.0%
Payout ratio
58.2%
Company profile
Exchange
NASDAQ Capital Market
Employees
2
IPO date
2025-02-20
Headquarters
New York City, NY, US
About Translational Development Acquisition Corp.

Translational Development Acquisition Corp., founded in 2022 and headquartered in New York, New York, currently conducts no significant business operations. Its primary goal is to complete a business combination, such as a merger, amalgamation, share exchange, asset acquisition, share purchase, or reorganization, with one or more companies.

Comparable companies

Translational Development Acquisition Corp. is most often compared with the following Financial Services names:

CEPCEPOFACTHCMAMACINTWOSZZLWLACU
More research on TDAC
TDAC technical analysis TDAC TheEdge Score Compare against peers
Open full interactive analysis & DCF →